Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486392 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 474
- Enrollment target
NCT03486392: Completed Phase 2 study, sponsored by Janssen Research & Development.
NCT03486392 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 474 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (256% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03486392, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 474 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
Primary Outcome
Percent change in body weight in kilograms (kg) from baseline to Week 26 was reported.
Interventions
- DRUG Placebo
- DRUG Liraglutide
- DRUG JNJ-64565111 Dose Level 1
- DRUG JNJ-64565111 Dose Level 2
- DRUG JNJ-64565111 Dose Level 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2019-03-08 |
| Phase | Phase 2 |
What the finished NCT03486392 record still lists
NCT03486392 is an interventional study that assigns participants to a tested intervention. The registered 474 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (256% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03486392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03486392 about?
NCT03486392 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants". The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
What is the current status of trial NCT03486392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2018-03-26. Estimated completion is 2019-03-08.
What interventions are being tested in trial NCT03486392?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG), JNJ-64565111 Dose Level 1 (DRUG), JNJ-64565111 Dose Level 2 (DRUG), JNJ-64565111 Dose Level 3 (DRUG).
Who is sponsoring clinical trial NCT03486392?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03486392's enrollment target sits among peer trials
474 77th of 2000 higher than 1,923 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT06051695 · 474 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- NCT06632977 · 474 participants · Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI